Short Communication - (2022) Volume 8, Issue 12
Received: 30-Nov-2022, Manuscript No. IPIC-23-15458; Editor assigned: 02-Dec-2022, Pre QC No. IPIC-23-15458 (PQ); Reviewed: 16-Dec-2022, QC No. IPIC-23-15458; Revised: 21-Dec-2022, Manuscript No. IPIC-23-15458 (R); Published: 28-Dec-2022, DOI: 10.21767/2471-8157.8.12.60
Radiofrequency ablation (RFA), also known as fulguration, is a medical procedure in which heat generated by medium frequency alternating current is used to ablate a portion of the electrical conduction system of the heart, a tumor, or other dysfunctional tissue. RFA is typically carried out in an outpatient setting and requires either local anesthetics or conscious sedation anesthesia. It is known as radiofrequency catheter ablation when it is administered through a catheter.
Compared to low-frequency AC or DC pulses, radio frequency current has two significant advantages: It does not directly stimulate nerves or heart muscle, so it can often be used without general anesthesia, and it is very specific for treating the desired tissue without causing a lot of collateral damage. It is becoming increasingly popular as an alternative for eligible patients who do not wish to undergo surgery as a result of this. RFA's documented benefits have led to its widespread application in the 21st century. An interventional pain specialist (such as an anesthesiologist), interventional radiologist, otolaryngologist, gastrointestinal or surgical endoscopist, or cardiac electrophysiologist, a subspecialty of cardiologists, perform RFA procedures under image guidance (such as X-ray screening, CT scan, or ultrasound) [1]. The treatment of tumors in the liver, kidney, bone, lung, and other less common organs can all benefit from RFA. A RFA probe resembling a needle is inserted within the tumor once the diagnosis of the tumor is confirmed. The temperature of the tumor tissue rises as a result of the probe's radiofrequency waves, which destroy the tumor [2,3]. Small tumors, whether primary tumors that originated within the organ or metastases that spread to the organ, can be treated with RFA. Multiple factors determine whether RFA is appropriate for a particular tumor [4]. Although RFA may occasionally necessitate a brief hospital stay, it can typically be administered out of the hospital. Hepatocellular carcinoma, also known as primary liver cancer, can be treated with RFA in conjunction with locally administered chemotherapy. As a treatment for hepatocellular carcinoma (HCC), a method that is currently in phase III trials makes use of the low-level heat (hyperthermia) generated by the RFA probe to cause the release of concentrated chemotherapeutic drugs from heat-sensitive liposomes in the margins surrounding the ablated tissue. In the treatment of osteoid osteomas and other benign bone tumors, RFA has become increasingly important. Numerous studies have demonstrated that the treatment for osteoid osteomas, which was first introduced in the 1990s, is less invasive, more cost-effective, causes less bone loss, and is as safe and effective as surgical procedures, with 66% to 95% of patients reporting relief from symptoms.
Removal is presently the standard treatment for SVT and common atrial ripple and the procedure can likewise be utilized in AF, either to hinder the atrioventricular hub after implantation of a pacemaker or to obstruct conduction inside the left chamber, particularly around the pneumonic veins. Cryoablation (tissue freezing using a coolant that flows through the catheter) can be used to perform ablation in some conditions, particularly forms of intra-nodal re-entry, also known as atrioventricular nodal reentrant tachycardia or AVNRT, which is the most common type of SVT. Cryoablation eliminates the risk of complete heart block, which is a potential complication of radiofrequency ablation in this condition.
The author is grateful to the journal editor and the anonymous reviewers for their helpful comments and suggestions.
The author declared no potential conflicts of interest for the research, authorship, and/or publication of this article.
[Crossref] [Google Scholar] [PubMed]
[Crossref] [Google Scholar] [PubMed]
[Crossref] [Google Scholar] [PubMed]
[Crossref] [Google Scholar] [PubMed]
Citation: Mezlekia N (2022) Radiofrequency Ablaion and Management of Sympatheic Denervaion. Interv Cardiol J.12:60.
Copyright: © 2022 Mezlekia N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
